Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| Triiodothyronine (T3) and thyroxine (T4) Thyroid hormone receptor agonist (AGONIST); direct interaction, disease efficacy true | Spinal cord injury · Ischaemia-reperfusion | 31980–2018 | No trauma translation | |
| Ulinastatin (urinary trypsin inhibitor) Biologic | Crush · Ischaemia-reperfusion +4 | 82011–2020 | Not approved | |
| Xenon ChEMBL records list diagnostic-agent and MRI contrast-agent mechanisms for xenon isotopes; ATC N01AX15 classifies xenon as a general anaesthetic. | Ischaemia-reperfusion · TBI | 32015–2020 | No trauma translation |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.